Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The global medical radioactive iodine I-131 market size was estimated at USD 811 million in 2025 and is predicted to increase from USD 862.74 million in 2026 to approximately USD 1505.29 million by 2035, expanding at a CAGR of 6.38% from 2026 to 2035.
The growing health awareness and expanding healthcare are increasing the use of medical radioactive iodine I-131 to tackle the growing thyroid diseases. The companies are also developing new products and are collaborating, which is promoting the market growth.
The medical radioactive iodine I-131 market is driven by growing thyroid disorders and its proven effectiveness in the targeted treatment. The medical radioactive iodine I-131 refers to the radioisotope of iodine, which is used for the diagnosis and treatment of thyroid-related disorders. This radioisotope emits beta and gamma radiation, which helps in the evaluation of thyroid functions, their abnormalities, and monitoring the treatment efficacy.
The radioisotope iodine I-131 is a very important medical treatment for hyperthyroidism and differentiated thyroid cancer because of its affinity to accumulate in the thyroid without harming surrounding normal organs. After surgery, I-131 also plays an important role in the management of residual thyroid cancer and the prevention of recurrence. Continuous advancements in nuclear medicine, the growing use of personalized treatment methods, and the increasing availability of specialized healthcare facilities are all helping to drive growth within this market. Growing awareness for early diagnosis of thyroid diseases, as well as successful clinical outcomes associated with I-131 therapy, will continue to increase demand for this therapy in all hospitals and all cancer and nuclear medicine facilities around the globe.
The use of AI in the medical radioactive iodine I-131 market is increasing, where it is being utilized for the analysis of patient data, which is promoting the development of personalized treatments, combination therapies, and other formulations, with enhanced efficacy and low radiation exposure. It also helps in the detection of various thyroid disorders, where it is also used to identify the disease progress, patient response to the therapy, and dose calculations.
Expanding Nuclear Medicine Facilities
There is a growth in the nuclear medicine facilities globally, where new collaborations are also expanding their services, which is increasing the development of medical radioactive iodine I-131.
Increasing Innovations
The companies are developing various medical radioactive iodine I-131 targeted, personalized, and combination therapies to enhance their efficacy, safety, applications, and reduce their side effects.
Growing Technological Advancements
Different types of diagnostic and drug delivery systems are being developed, where the companies are also focusing on integrating modern imaging techniques with medical radioactive iodine I-131 to enhance their detection, treatment, and monitoring outcomes.
| Key Elements | Scope |
| Market Size in 2026 | USD 862.74 Million |
| Projected Market Size in 2035 | USD 1505.29 Million |
| CAGR (2026 - 2035) | 6.38% |
| Leading Region | North America |
| Key Applications | Thyroid cancer therapy, Hyperthyroidism treatment, Diagnostic imaging, Radioiodine ablation, Neuroendocrine tumor therapy (I-131 MIBG), Nuclear medicine procedures |
| Primary End Users | Hospitals, Nuclear Medicine Centers, Oncology Centers, Academic Medical Centers, Specialty Clinics, Research Institutes |
| Key Challenges | Limited reactor-based isotope production, short isotope half-life, complex logistics, stringent regulatory requirements, radiation safety compliance, supply chain disruptions |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Application, By Product, By End User, By Distribution Channel, By Region |
| Top Key Players | Jubilant Draxlmage, NTP Radioisotopes, Curium Pharma, POLATOM, Isotope JSC, Nordion Inc., Cardinal Health |
Why Did the Diagnostic Segment Dominate in the Market in 2025?
The diagnostic segment led the medical radioactive iodine I-131 market in 2025, as they were essential in thyroid cancer detection. They offered enhanced accuracy with lower doses, which increased their use in the various thyroid function tests. Moreover, their non-invasive approach and affordability also increased their acceptance rates.
Therapeutic
The therapeutic segment is expected to show the highest growth during the upcoming years, due to growing thyroid cancer rates. The medical radioactive iodine I-131 also offers enhanced effectiveness, which is increasing its demand. Additionally, increasing health awareness is also increasing their use and innovations.
Which Product Type Segment Held the Dominating Share of the Market in 2025?
The capsule segment held the dominating share in the medical radioactive iodine I-131 market in 2025, due to its longer shelf life. Their easy use and consistent dosing also increased their demand, which enhanced patient compliance. Furthermore, they also offered easy and simple storage and transportation, which increased their adoption rates.
Solution
The solution segment is expected to show rapid growth during the upcoming years, driven by its flexible dosing. The rising paediatric and geriatric population is also increasing its use. Moreover, their personalized dosing and faster absorption rates are also increasing their demand and adoption rates.
How Hospitals Segment Dominated the Market in 2025?
The hospitals segment led the medical radioactive iodine I-131 market in 2025, due to the presence of specialized nuclear medicine departments. At the same time, the presence of radiation safety infrastructure and skilled personnel handling high-dose therapeutic products also attracted the patient. Additionally, advanced diagnostic techniques also increased their dependence.
Clinics
The clinics segment is expected to show the highest growth during the predicted time, due to the growing number of outpatients. This is increasing the use of medical radioactive iodine I-131 for the diagnosis and treatment of various thyroid diseases. They also offer an affordable solution, which is increasing their demand.
Diagnostic Lab
In the clinics segment, the diagnostic lab subsegment is expected to show the fastest growth rate during the forecast period, due to growing health awareness, which is increasing the use of medical radioactive iodine I-131 for thyroid function tests and imaging. Additionally, expanding labs and high patient volumes are also increasing their use.
What Made Hospital Pharmacy the Dominant Segment in the Market in 2025?
The hospital pharmacy segment held the largest share in the medical radioactive iodine I-131 market in 2025, due to the stringent radiation handling and storage facilities. They also offered integration with nuclear medicine and the therapeutic department, which maintained the availability of medical radioactive iodine I-131, increasing their acceptance rates.
Retail Pharmacy
The retail pharmacy segment is expected to show rapid growth during the predicted time, due to growing outpatient volume. The growing demand for low-dose I-131 for diagnostic applications is also increasing its use. Additionally, their widespread availability is also increasing the reliance on them.
North America dominated the medical radioactive iodine I-131 market in 2025, due to the presence of a well-established nuclear medicine infrastructure. The growing thyroid disorders are also increasing their use. Moreover, the advanced healthcare infrastructures and reimbursement policies also increased their use, which contributed to the market growth.
U.S. Market Trends
The U.S. consists of an advanced healthcare infrastructure, which is driving the early adoption of various personalized and targeted medical radioactive iodine I-131 treatment options. The growing thyroid cancer cases and increasing healthcare investments are also increasing their demand and encouraging their advancements.
Canada Market Trends
An increasing incidence of thyroid cancer and hyperthyroidism, along with a growing use of procedures using nuclear medicine and a well-established healthcare system, contributes to the expansion of the I-131 market for medical radioiodine in Canada. Additionally, strong governmental support for cancer treatment, the increased availability of radiopharmaceuticals, and continued investments into both diagnostic and therapeutic nuclear medicine are all factors driving demand for I-131 in hospitals and specialty clinics.
Mexico Market Trends
The market for I-131 medical radioiodine continues to grow at a steady pace in Mexico due to the increasing diagnosis of patients with thyroid disorders, an increased number of nuclear medicine services, and improvement in the country’s healthcare system. Growing awareness of the benefits of radioisotope-based treatment, improved access by patients to specialized oncology care, and increased investments in advanced imaging techniques have resulted in increased use of I-131 in the practice of medicine.
Asia Pacific is expected to host the fastest-growing medical radioactive iodine I-131 market during the forecast period, due to growing thyroid disorders, which are increasing the use of medical radioactive iodine I-131 for their early and effective diagnosis and treatment. The expanding healthcare and growing awareness are also enhancing the market growth.
China Market Trends
China is experiencing a rise in thyroid disorders, which is increasing the demand for medical radioactive iodine I-131 solutions. The expanding healthcare and growing government initiatives are also increasing their adoption rates, where increasing investments are driving their innovations.
India Market Trends
The growth of the market for medical radioactive iodine I-131 in India appears to be increasing rapidly due to a number of factors: the growing burden of thyroid disease, the growing number of facilities to treat cancers and increased use of nuclear medicine. Furthermore, government initiatives focused on improving health care infrastructure, increasing investment in the production of radiopharmaceuticals and the increase of the number of specialized centers with access to such treatments will all help drive continued growth in this marketplace.
Japan Market Trends
Japan's medical market for radioactive iodine I-131 continues to benefit from its advanced health care system, the large proportion of its population who are elderly, and very high levels of use of nuclear medicine technologies. In addition, the increasing incidence of thyroid disease, the vast clinical experience with radiopharmaceuticals as therapeutic agents in Japan and the continued introduction of new technology into both diagnostic and therapeutic uses will continue to drive demand for I-131 in the Japanese marketplace.
Europe is expected to grow significantly in the medical radioactive iodine I-131 market during the forecast period, due to the presence of advanced healthcare systems, which are increasing the availability of medical radioactive iodine I-131. The stringent regulations, growing innovations, and increased thyroid disease are also promoting the market growth.
The presence of a well-developed nuclear medicine infrastructure and healthcare system is increasing the development and use of medical radioactive iodine I-131. The growing health awareness and government support are also increasing their use for early detection and effective management of thyroid diseases.
Germany Market Trends
Germany is at the forefront of the medical radioactive iodine I-131 market in Europe with a strong nuclear medicine sector, an effective healthcare system, and wide adoption of precision therapies using targeted radiopharmaceuticals. With a high demand for effective treatment of thyroid cancer, a large amount of research being done in this field, and many dedicated specialist centres, Germany's medical radioactive iodine I-131 market will continue to grow.
Netherlands Market Trends
The Netherlands has a flourishing medical radioactive iodine I-131 market, thanks to its highly developed healthcare system, increased use of nuclear medicine, and greater efforts to implement precision strategies for cancer. The increasing need for effective treatment of thyroid end in cancer, as well as the expanding number of specialist centres to provide radiopharmaceutical services, will continue to cause growth in the market.
UK Market Trends
The UK is one of the most important markets in the world for medical radioactive iodine I-131, driven by the high rate of thyroid cancer cases diagnosed each year, a well-established network of nuclear medicine services, and a strong commitment to developing and implementing precision cancer therapies. The continuing adoption of radiopharmaceutical therapies and the continued investment in the development and maintenance of specialist health services will ensure that the UK remains an essential player in the medical radioactive iodine I-131 market for many years to come.
| Ecosystem Segment | Description |
| Technology Providers | Nuclear reactor operators, isotope production technology developers, radiochemistry equipment manufacturers, hot-cell technology providers. |
| Product Manufacturers | Manufacturers producing I-131 sodium iodide capsules, oral solutions, I-131 MIBG products, therapeutic radiopharmaceuticals, and isotope generators. |
| Service Providers | Nuclear pharmacy networks, radiopharmaceutical distributors, isotope logistics providers, radiation safety services, clinical treatment providers. |
| Platform Providers | Radiopharmaceutical manufacturing platforms, isotope processing facilities, GMP production infrastructure, nuclear medicine supply chain operators. |
| CROs/CDMOs | Contract manufacturers specializing in sterile radiopharmaceutical production, isotope labeling, GMP manufacturing, and regulatory support. |
| Software Vendors | Nuclear medicine workflow software, dosimetry platforms, radiation planning software, imaging informatics vendors. |
| Research Institutions | National laboratories, nuclear research institutes, university hospitals, cancer research centers, isotope development organizations. |
| End-User Industries | Hospitals, cancer centers, endocrinology clinics, nuclear medicine departments, academic institutions, pharmaceutical companies. |
R&D
Clinical Trials and Regulatory Approvals
Patient Support and Services
| Tier 1 | Tier 2 | Tier 3 | |
| Typical Market Influence | 68% | 22% | 10% |
| Tier 1 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Curium | Paris | France | Global leader in nuclear medicine with extensive commercial I-131 portfolio and worldwide distribution | Sodium Iodide I-131, diagnostic and therapeutic radiopharmaceuticals |
| GE HealthCare | Chicago, Illinois | United States | Major global nuclear medicine supplier with broad radiopharmaceutical manufacturing and distribution capabilities | I-131 products, nuclear medicine portfolio, imaging solutions |
| Eckert & Ziegler | Berlin | Germany | Leading isotope manufacturer with extensive isotope production and radiopharmaceutical capabilities | I-131 isotopes, radioisotopes, radiopharmaceutical manufacturing |
| Tier 2 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| ITM Isotope Technologies Munich SE | Garching, Bavaria | Germany | Established radiopharmaceutical company with isotope production expertise and expanding therapeutic portfolio | Medical radioisotopes, isotope supply, therapeutic radionuclides |
| POLATOM (Radioisotope Centre POLATOM) | Otwock | Poland | Major European producer of therapeutic radioisotopes including I-131 | Sodium Iodide I-131, therapeutic radioisotopes |
| NorthStar Medical Radioisotopes | Beloit, Wisconsin | United States | Growing isotope manufacturer expanding domestic medical isotope production | Medical radioisotopes, isotope manufacturing |
| Tier 3 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Telix Pharmaceuticals | North Melbourne, Victoria | Australia | Expanding therapeutic radiopharmaceutical portfolio with strategic isotope capabilities | Therapeutic radiopharmaceutical development |
| Alpha Nuclides | Beltsville, Maryland | United States | Specialized supplier of medical radioisotopes including I-131 for clinical and research applications | I-131 radioisotopes, isotope distribution |
| Global Medical Solutions Ltd. (GMS) | Abu Dhabi | United Arab Emirates | Regional manufacturer and distributor of radiopharmaceuticals serving Middle East markets | I-131 radiopharmaceutical production |
Strengths
Weaknesses
Opportunities
Threats
In January 2025, Mihály Lakatos, Managing Director of Institute of Isotopes Co. Ltd., commented: “Our collaboration with Curium in the field of iodine-131 products allows us to provide nuclear medicine laboratories operating in several European countries with the availability of products containing the I-131 isotope, which is essential for thyroid treatments. Our production areas are prepared to produce the medicines necessary for the diagnosis and therapy of thyroid cancer, and our collaboration with Curium allows us to provide the available treatment to as many patients as possible.”
By Application
By Product
By End User
By Distribution Channel
By Region
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
